About mosunetuz umab
CD20×CD3 bispecific antibody
Used for
- Treats adults with relapsed or refractory follicular lymphoma after at least two previous treatments.
Usual adult dose
Given by IV infusion in step-up doses over 21-day cycles: 1 mg day 1, 2 mg day 8, then 60 mg day 15; later doses depend on response and cycle.
Common side effects
- Cytokine release syndrome (fever, chills, low blood pressure)
- Tiredness, rash, headache
- Low blood cell counts
- Infections
Important warnings
- Cytokine release syndrome can be serious, especially during early doses.
- Serious neurological problems, including confusion or seizures, can occur.
- Treatment can cause severe infections and low blood counts.
- Only trained clinicians should give this medicine with appropriate monitoring.
Pregnancy
May harm an unborn baby. Avoid pregnancy during treatment and for at least three months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment or for at least three months after the last dose.
Interactions
- Live vaccines should be avoided during treatment and until immune recovery.
- Tell the treatment team about all medicines, as interactions may affect safety or effectiveness.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.